Dosing & Uses
Dosage Forms & Strengths
tablet: Schedule II
- Ritalin
- 5mg
- 10mg
- 20mg
capsule, extended-release: Schedule II
- 10mg (Aptensio XR, Ritalin LA, Metadate CD)
- 15mg (Aptensio XR)
- 20mg (Aptensio XR, Ritalin LA, Metadate CD)
- 25mg (Adhansia XR)
- 30mg (Aptensio XR, Ritalin LA, Metadate CD)
- 35mg (Adhansia XR)
- 40mg (Aptensio XR, Ritalin LA, Metadate CD)
- 45mg (Adhansia XR)
- 50mg (Aptensio XR, Metadate CD)
- 55mg (Adhansia XR)
- 60mg (Aptensio XR, Ritalin LA, Metadate CD)
- 70mg (Adhansia XR)
- 85mg (Adhansia XR)
capsule, extended release/delayed release: Schedule II
- 20mg (Jornay PM)
- 40mg (Jornay PM)
- 60mg (Jornay PM)
- 80mg (Jornay PM)
- 100mg (Jornay PM)
tablet, extended-release: Schedule II
- 10mg (Methylin, generics)
- 18mg (Concerta, Relexxii)
- 20mg (Methylin, generics)
- 27mg (Concerta, Relexxii)
- 36mg (Concerta, Relexxii)
- 45mg (Relexxii)
- 54mg (Concerta, Relexxii)
- 63mg (Relexxii)
- 72mg (Relexxii)
extended-release tablet, chewable (scored): Schedule II
- QuilliChew ER
- 20mg
- 30mg
- 40mg
tablet, chewable: Schedule II
- Methylin
- 2.5mg
- 5mg
- 10mg
oral solution: Schedule II
- Methylin
- 5mg/5mL
- 10mg/5mL
Attention Deficit Hyperactivity Disorder
Adhansia XR: 25 mg PO qAM initially; may titrate upward in increments of 10-15 mg at intervals of at least 5 days; dosages >85 mg/day associated with increased incidence of certain adverse reactions
Aptensio XR: 10 mg PO qDay in AM; may increase weekly by 10-mg increments; not to exceed 60 mg/day
Concerta: Initial for methylphenidate-naïve, 18-36 mg PO qDay; may increase by 18-mg increments at weekly intervals; maintenance dose is 18-72 mg/day
Metadate CD: Initial, 20 mg PO qAM before breakfast; may increase in 10- to 20-mg increments; not to exceed 60 mg/day
Methylin ER: Duration of action ~8 hr; may use in place of methylphenidate IR tablets when 8-hr dosage of methylphenidate ER corresponds to titrated 8-hr dosage of methylphenidate IR; not to exceed 60 mg/day
Ritalin (immediate-release tablets and oral solution): 20-30 mg/day PO divided q8-12hr, 30-45 minutes before meals; may gradually increase dose at weekly intervals; some patients may require 40-60 mg/day; in others, 10-15 mg/day may be adequate
QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may titrate up or down weekly in increments of 10 mg, 15 mg, or 20 mg; not to exceed 60 mg/day
Jornay PM: Initial, 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day; initiate dosing at 8:00 pm; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day
Relexxii: Initial for methylphenidate-naïve, 18-36 mg PO qDay; may increase by 18-mg increments at weekly intervals; maintenance dose is 18-72 mg/day; not to exceed 72 mg/day
Ritalin LA: Initial, 20 mg PO qAM; may adjust dose in weekly 10-mg increments, not to exceed 60 mg/day (patients requiring a lower initial dose may begin with 10 mg)
Narcolepsy
Methylin, Ritalin (immediate-release tablets and oral solution): 20-30 mg/day PO divided q8-12hr, 30-45 minutes before meals; some patients may require 40-60 mg/day; in others, 10-15 mg/day may be adequate
Methylin ER: Duration of action is approximately 8 hr; may use in place of methylphenidate IR tablets when 8-hr dosage of methylphenidate ER corresponds to the titrated 8-hr dosage of methylphenidate IR
Dosage Modifications
Dose reduction and discontinuation
- If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage, or, if necessary, discontinue drug
- Periodically discontinue treatment to assess condition
- If improvement not observed after appropriate dosage adjustment over a one-month period, discontinue treatment
Conversion from methylphenidate to Concerta or Relexxii
- Currently on methylphenidate 5 mg BID or TID: Start Concerta or Relexxii at 18 mg qAM
- Currently on methylphenidate 10 mg BID or TID: Start Concerta or Relexxii at 36 mg qAM
- Currently on methylphenidate 15 mg BID or TID: Start Concerta or Relexxii at 54 mg qAM
- Currently on methylphenidate 20 mg BID or TID: Start Concerta or Relexxii at 72 mg qAM
Renal impairment
- Since renal clearance is not an important route of clearance, renal insufficiency is expected to have little effect on pharmacokinetics of methylphenidate ER tablets
Hepatic impairment
- \No experience with use in patients with hepatic insufficiency
Dosing Considerations
Before initiating
- Assess for presence of cardiac disease (eg, family history of sudden death or ventricular arrhythmia)
- Assess risk of abuse before prescribing and monitor for signs of abuse and dependence during therapy
- Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate need for use
Dosage Forms & Strengths
tablet: Schedule II
- Ritalin
- 5mg
- 10mg
- 20mg
capsule, extended-release: Schedule II
- 10mg (Aptensio XR, Ritalin LA, Metadate CD)
- 15mg (Aptensio XR)
- 20mg (Aptensio XR, Ritalin LA, Metadate CD)
- 25mg (Adhansia XR)
- 30mg (Aptensio XR, Ritalin LA, Metadate CD)
- 35mg (Adhansia XR)
- 40mg (Aptensio XR, Ritalin LA, Metadate CD)
- 45mg (Adhansia XR)
- 50mg (Aptensio XR, Metadate CD)
- 55mg (Adhansia XR)
- 60mg (Aptensio XR, Ritalin LA, Metadate CD)
- 70mg (Adhansia XR)
- 85mg (Adhansia XR)
capsule, extended release/delayed release: Schedule II
- 20mg (Jornay PM)
- 40mg (Jornay PM)
- 60mg (Jornay PM)
- 80mg (Jornay PM)
- 100mg (Jornay PM)
tablet, extended-release: Schedule II
- 10mg (Methylin, generics)
- 18mg (Concerta, Relexxii)
- 20mg (Methylin, generics)
- 27mg (Concerta, Relexxii)
- 36mg (Concerta, Relexxii)
- 45mg (Relexxii)
- 54mg (Concerta, Relexxii)
- 63mg (Relexxii)
- 72mg (Relexxii)
extended-release tablet, chewable (scored): Schedule II
- QuilliChew ER
- 20mg
- 30mg
- 40mg
tablet, chewable: Schedule II
- Methylin
- 2.5mg
- 5mg
- 10mg
transdermal patch: Schedule II
- Daytrana
- 10mg
- 15mg
- 20mg
- 30mg
oral solution: Schedule II
- Methylin
- 5mg/5mL
- 10mg/5mL
oral suspension, extended-release: Schedule II
- Quillivant XR
- 25mg/5mL (following reconstitution)
extended-release tablet, oral disintegrating
- Cotempla XR-ODT
- 8.6mg
- 17.3mg
- 25.9mg
Attention Deficit Hyperactivity Disorder
<6 years: Safety and efficacy not established
≥6 years
- Aptensio XR: 10 mg PO qDay in AM; may increase weekly by 10-mg increments; not to exceed 60 mg/day
- Adhansia XR: 25 mg PO qAM initially; may titrate up in increments of 10-15 mg at intervals of at least 5 days; dosages ≥70 mg/day associated with increased incidence of certain adverse reactions
- Cotempla XR-ODT (oral disintegrating tablets): 17.3 mg PO qAM initially; may titrate upward weekly by 8.6-17.3 mg increments; not to exceed 51.8 mg/day
- Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO BID 30-45 minutes before breakfast and lunch initially; may increase by 5-10 mg/day at weekly intervals; not to exceed 60 mg/day divided BID/TID
- Methylin ER: May be given in place of immediate-release products once daily dose is titrated and the titrated 8-hr dosage corresponds to SR or ER tablet size; not to exceed 60 mg/day
- Metadate CD, Ritalin LA: Initial, 20 mg PO qAM; may increase by 10 mg (Ritalin LA) or 10-20 mg (Metadate CD) qWeek to not to exceed 60 mg/day
- Quillivant XR (6-12 years): 20 mg PO qAM initially; may titrate at weekly intervals by weekly 10- to 20-mg increments; not to exceed 60 mg/day
- QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may be titrated up or down weekly in increments of 10 mg, 15 mg, or 20 mg, not to exceed 60 mg/day
-
Immediate-release weight-based dosing
-
Concerta or Relexxii (methylphenidate-naïve)
- Initial: 18 mg PO qDay; dosage may be increased by 18 mg/day at weekly intervals
- Do not exceed 54 mg/day in children (6-12 years) and 72 mg/day in adolescents (13-17 years)
-
Jornay PM
- Initial: 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day
- Initiate dosing at 8:00 p.m.; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day
Narcolepsy
<6 years
- Safety and efficacy not established
≥6 years
- Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO q12hr; may increase by 5-10 mg/day weekly; not to exceed 60 mg/day
- Methylin ER,: May be given in place of immediate-release products once the daily dose is titrated and the titrated 8-hour dosage corresponds to ER tablet size; not to exceed 60 mg/day
Dosage Modifications
Dose reduction and discontinuation
- If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage, or, if necessary, discontinue drug
- Periodically discontinue treatment to assess condition
- If improvement not observed after appropriate dosage adjustment over a one-month period, discontinue treatment
Conversion from methylphenidate to Concerta or Relexxii
- Currently on methylphenidate 5 mg BID or TID: Start Concerta or Relexxii at 18 mg qAM
- Currently on methylphenidate 10 mg BID or TID: Start Concerta or Relexxii at 36 mg qAM
- Currently on methylphenidate 15 mg BID or TID: Start Concerta or Relexxii at 54 mg qAM
- Currently on methylphenidate 20 mg BID or TID: Start Concerta or Relexxii at 72 mg qAM
Renal impairment
- Since renal clearance is not an important route of clearance, renal insufficiency is expected to have little effect on pharmacokinetics of methylphenidate ER tablets
Hepatic impairment
- No experience with use in patients with hepatic insufficiency
Dosing Considerations
Before initiating
- Assess for presence of cardiac disease (eg, family history of sudden death or ventricular arrhythmia)
- Assess risk of abuse before prescribing and monitor for signs of abuse and dependence while on therapy
- Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate the need for use
Limitations of use (Aptensio XR)
- Patients <6 years of age experienced higher plasma exposure than patients aged ≥6 at the same dose and high rates of adverse reactions, most notably weight loss
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (12)
- benzphetamine
benzphetamine increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- diethylpropion
diethylpropion increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- isocarboxazid
isocarboxazid increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI.
- linezolid
linezolid increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- phendimetrazine
phendimetrazine increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- phenelzine
phenelzine increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI.
- phentermine
phentermine increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
- rasagiline
rasagiline increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI.
- safinamide
safinamide increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI.
- selegiline
selegiline increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI.
- selegiline transdermal
selegiline transdermal increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI.
- tranylcypromine
tranylcypromine increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI.
Serious - Use Alternative (18)
- cabergoline
cabergoline, methylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.
- desflurane
desflurane increases toxicity of methylphenidate by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of acute hypertensive episode.
- dihydroergotamine
dihydroergotamine, methylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.
- dihydroergotamine intranasal
dihydroergotamine intranasal, methylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.
- doxapram
doxapram increases effects of methylphenidate by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive pressor effect.
- ergoloid mesylates
ergoloid mesylates, methylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.
- ergotamine
ergotamine, methylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.
- ethanol
ethanol increases levels of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Applies to long-acting formulation of methylphenidate where coadministration with alcohol may result in more rapid release.
- ether
ether increases toxicity of methylphenidate by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of V tach, HTN.
- iobenguane I 123
methylphenidate decreases effects of iobenguane I 123 by Other (see comment). Avoid or Use Alternate Drug. Comment: Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose.
- isoflurane
isoflurane increases toxicity of methylphenidate by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of acute hypertensive episode.
- lofepramine
lofepramine, methylphenidate. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- maprotiline
maprotiline, methylphenidate. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- methoxyflurane
methoxyflurane increases toxicity of methylphenidate by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of V tach, HTN.
- methylergonovine
methylergonovine, methylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension.
- ozanimod
ozanimod increases toxicity of methylphenidate by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.
- sevoflurane
sevoflurane increases toxicity of methylphenidate by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of acute hypertensive episode.
- yohimbe
yohimbe, methylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.
Monitor Closely (143)
- albuterol
albuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- aluminum hydroxide
aluminum hydroxide decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided.
- amitriptyline
amitriptyline, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- amlodipine
methylphenidate will decrease the level or effect of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- amoxapine
amoxapine, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- apomorphine
apomorphine, methylphenidate. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS stimulation.
- arformoterol
arformoterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- aripiprazole
aripiprazole increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- armodafinil
armodafinil increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- asenapine
asenapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- aspirin/citric acid/sodium bicarbonate
aspirin/citric acid/sodium bicarbonate decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided.
- atomoxetine
methylphenidate will increase the level or effect of atomoxetine by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- azilsartan
methylphenidate will decrease the level or effect of azilsartan by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- benazepril
methylphenidate will decrease the level or effect of benazepril by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen, methylphenidate. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
- bromocriptine
bromocriptine, methylphenidate. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS stimulation.
- caffeine
caffeine increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- calcium carbonate
calcium carbonate decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided.
- candesartan
methylphenidate will decrease the level or effect of candesartan by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- captopril
methylphenidate will decrease the level or effect of captopril by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- carbamazepine
carbamazepine decreases effects of methylphenidate by unspecified interaction mechanism. Use Caution/Monitor. Monitor for decreased therapeutic effects of methylphenidate if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased.
- cariprazine
cariprazine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- chlorpromazine
chlorpromazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.
- cimetidine
cimetidine decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided.
- clevidipine
methylphenidate will decrease the level or effect of clevidipine by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- clomipramine
clomipramine, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- clozapine
clozapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- cocaine topical
cocaine topical increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- desipramine
desipramine, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dexfenfluramine
dexfenfluramine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- dexlansoprazole
dexlansoprazole decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided.
- dexmethylphenidate
dexmethylphenidate increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- dextroamphetamine
dextroamphetamine increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- didanosine
didanosine will decrease the level or effect of methylphenidate by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Interaction specifically associated with Ritalin LA.
- diltiazem
methylphenidate will decrease the level or effect of diltiazem by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- dobutamine
dobutamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- dopamine
dopamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- dopexamine
dopexamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- doxepin
doxepin, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dronabinol
methylphenidate will increase the level or effect of dronabinol by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- enalapril
methylphenidate will decrease the level or effect of enalapril by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- ephedrine
ephedrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- epinephrine
epinephrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- epinephrine inhaled
methylphenidate, epinephrine inhaled. Either increases effects of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- epinephrine racemic
epinephrine racemic and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- eprosartan
methylphenidate will decrease the level or effect of eprosartan by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- esketamine intranasal
esketamine intranasal, methylphenidate. Either increases toxicity of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Closely monitor blood pressure with concomitant use of esketamine nasal with stimulants. .
- esomeprazole
esomeprazole decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided.
- famotidine
famotidine will increase the level or effect of methylphenidate by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Applies only to extended release formulation
famotidine decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. - felodipine
methylphenidate will decrease the level or effect of felodipine by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- fenfluramine
fenfluramine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- fluphenazine
fluphenazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.
fluphenazine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. - formoterol
formoterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- fosinopril
methylphenidate will decrease the level or effect of fosinopril by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- fosphenytoin
methylphenidate will increase the level or effect of fosphenytoin by unknown mechanism. Use Caution/Monitor. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased.
- green tea
green tea, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Green tea may include caffeine. Caffeine is a CNS-stimulant and additive effects may be seen when coadministered with other CNS stimulants. Caffeine should be avoided or used cautiously.
- haloperidol
haloperidol increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- hydralazine
hydralazine, methylphenidate. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Sympathomimetics can antagonize the activity of some antihypertensive agents.
- hydrocodone
hydrocodone, methylphenidate. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
- ibuprofen/famotidine
ibuprofen/famotidine will increase the level or effect of methylphenidate by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Applies only to extended release formulation
- iloperidone
iloperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- imipramine
imipramine, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- iohexol
methylphenidate decreases effects of iohexol by unspecified interaction mechanism. Modify Therapy/Monitor Closely. CNS stimulant should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours postprocedure.
- iopamidol
methylphenidate decreases effects of iopamidol by unspecified interaction mechanism. Modify Therapy/Monitor Closely. CNS stimulant should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours postprocedure.
- irbesartan
methylphenidate will decrease the level or effect of irbesartan by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- isoproterenol
isoproterenol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- isradipine
methylphenidate will decrease the level or effect of isradipine by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- lansoprazole
lansoprazole decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided.
- levalbuterol
levalbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- levodopa
levodopa, methylphenidate. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS stimulation.
- lisdexamfetamine
lisdexamfetamine increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- lisinopril
methylphenidate will decrease the level or effect of lisinopril by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- losartan
methylphenidate will decrease the level or effect of losartan by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- loxapine
loxapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- loxapine inhaled
loxapine inhaled increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- lurasidone
lurasidone, methylphenidate. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for additive CNS effects.
lurasidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. - magnesium oxide
magnesium oxide decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided.
- metaproterenol
metaproterenol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- methamphetamine
methamphetamine increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- methyldopa
methyldopa increases effects of methylphenidate by unknown mechanism. Use Caution/Monitor.
- modafinil
modafinil increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- moexipril
methylphenidate will decrease the level or effect of moexipril by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- molindone
molindone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- nadolol
methylphenidate will decrease the level or effect of nadolol by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- nicardipine
methylphenidate will decrease the level or effect of nicardipine by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- nifedipine
methylphenidate will decrease the level or effect of nifedipine by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- nimodipine
methylphenidate will decrease the level or effect of nimodipine by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- nisoldipine
methylphenidate will decrease the level or effect of nisoldipine by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- nizatidine
nizatidine will increase the level or effect of methylphenidate by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Applies only to extended release formulation
nizatidine decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. - norepinephrine
norepinephrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- nortriptyline
nortriptyline, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- olanzapine
olanzapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- olmesartan
methylphenidate will decrease the level or effect of olmesartan by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- omeprazole
omeprazole decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided.
- oxytocin
oxytocin increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor.
- paliperidone
paliperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- pantoprazole
pantoprazole decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided.
- penbutolol
methylphenidate will decrease the level or effect of penbutolol by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- perindopril
methylphenidate will decrease the level or effect of perindopril by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- perphenazine
perphenazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.
perphenazine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. - phenobarbital
methylphenidate will increase the level or effect of phenobarbital by unknown mechanism. Use Caution/Monitor. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased.
- phenoxybenzamine
methylphenidate will decrease the level or effect of phenoxybenzamine by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- phentolamine
methylphenidate will decrease the level or effect of phentolamine by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- phenytoin
methylphenidate will increase the level or effect of phenytoin by unknown mechanism. Use Caution/Monitor. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased.
- pimavanserin
pimavanserin increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- pimozide
pimozide increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- pirbuterol
pirbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- pramipexole
pramipexole, methylphenidate. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS stimulation.
- prazosin
methylphenidate will decrease the level or effect of prazosin by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- procarbazine
procarbazine increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.
- prochlorperazine
prochlorperazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.
- promazine
promazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.
- promethazine
promethazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.
- propranolol
methylphenidate will decrease the level or effect of propranolol by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- protriptyline
protriptyline, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- quetiapine
quetiapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- quinapril
methylphenidate will decrease the level or effect of quinapril by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- rabeprazole
rabeprazole decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided.
- ramipril
methylphenidate will decrease the level or effect of ramipril by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- risperidone
risperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- ropinirole
ropinirole, methylphenidate. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS stimulation.
- rotigotine
rotigotine, methylphenidate. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS stimulation.
- sacubitril/valsartan
methylphenidate will decrease the level or effect of sacubitril/valsartan by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- salmeterol
salmeterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- serdexmethylphenidate/dexmethylphenidate
serdexmethylphenidate/dexmethylphenidate and methylphenidate both decrease sedation. Use Caution/Monitor.
serdexmethylphenidate/dexmethylphenidate and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
serdexmethylphenidate/dexmethylphenidate increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode. - sodium zirconium cyclosilicate
sodium zirconium cyclosilicate will increase the level or effect of methylphenidate by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Check specific recommendations for drugs that exhibit pH-dependent solubility that may affect their systemic exposure and efficacy. In general, administer drugs at least 2 hr before or after sodium zirconium cyclosilicate. Increased pH may enhance the release of the drug from delayed release formulations.
- solriamfetol
methylphenidate and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- sotalol
methylphenidate will decrease the level or effect of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- sufentanil SL
sufentanil SL, methylphenidate. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
- telmisartan
methylphenidate will decrease the level or effect of telmisartan by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- terazosin
methylphenidate will decrease the level or effect of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- terbutaline
terbutaline and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- thioridazine
thioridazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.
- thiothixene
thiothixene increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
- timolol
methylphenidate will decrease the level or effect of timolol by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- trandolapril
methylphenidate will decrease the level or effect of trandolapril by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- trazodone
methylphenidate increases toxicity of trazodone by Other (see comment). Modify Therapy/Monitor Closely. Comment: Methylphenidate may increase serotonin release of agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity.
- trifluoperazine
trifluoperazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.
trifluoperazine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. - trimipramine
trimipramine, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- valsartan
methylphenidate will decrease the level or effect of valsartan by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- verapamil
methylphenidate will decrease the level or effect of verapamil by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
- warfarin
methylphenidate increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor.
- ziprasidone
ziprasidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination.
Minor (5)
- amantadine
amantadine, methylphenidate. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Potential for additive CNS stimulation.
- American ginseng
American ginseng increases effects of methylphenidate by pharmacodynamic synergism. Minor/Significance Unknown.
- desmopressin
desmopressin increases effects of methylphenidate by pharmacodynamic synergism. Minor/Significance Unknown.
- guarana
guarana increases effects of methylphenidate by pharmacodynamic synergism. Minor/Significance Unknown.
- yerba mate
yerba mate increases effects of methylphenidate by pharmacodynamic synergism. Minor/Significance Unknown.
Adverse Effects
>10%
ER capsules (adults)
- Insomnia (16%)
- Decreased appetite (11%)
Adhansia XR (patients aged 6-12 years)
- Decreased appetite (35%)
- Upper abdominal pain (15%)
- Affect lability (13%)
- Nausea or vomiting (13%)
- Decreased weight (12%)
Adhansia XR (patients aged 12-17 years)
- Decreased appetite (20%)
Aptensio XR
- Headache (10.9%)
Concerta or Relexxii (adults)
- Decreased appetite (25.3%)
- Headache (22.2%)
- Dry mouth (14%)
- Nausea (12.8%)
- Insomnia (12.3%)
Jornay PM
- Any insomnia (33%)
- Decreased appetite (19%)
Metadate CD
- Headache (12%)
1-10%
Adhansia XR (adults)
- Dry mouth (9%)
- Initial insomnia (6%)
- Nausea (6%)
- Diarrhea (4%)
- Feeling jittery (4%)
- Decreased weight (4%)
- Headache (4%)
- Fatigue (3%)
- Upper respiratory tract infection (2%)
- Irritability (2%)
- Nausea (2%)
- Dysmenorrhea (2%)
Adhansia XR (patients aged 6-12 years)
- Insomnia (10%)
- Irritability (10%)
- Headache (10%)
- Heart rate increased (5%)
Adhansia XR (patients aged 12-17 years)
- Weight decreased (7%)
- Insomnia (6%)
- Nausea (6%)
- Initial insomnia (5%)
- Upper abdominal pain (4%)
- Dizziness (3%)
- Dry mouth (3%)
- Vomiting (3%)
Aptensio XR
- Insomnia (9.8%)
- Upper abdominal pain (8.2%)
- Decreased appetite (4.9%)
- Nausea or vomiting (3.8%)
- Dizziness (2.2%)
Concerta or Relexxii (pediatric patients)
- Upper abdominal pain (6.2%)
- Irritability (5.8%)
- Vomiting (2.8%)
- Nasopharyngitis (2.8%)
- Insomnia (2.8%)
- Pyrexia (2.2%)
- Dyspepsia (2.2%)
- Dizziness (1.9%)
- Cough (1.9%)
- Vomiting (1.7%)
- Constipation (1.4%)
- Oropharyngeal pain (1.2%)
Concerta or Relexxii (adults)
- Anxiety (8.2%)
- Dizziness (6.7%)
- Decreased weight (6.5%)
- Hyperhidrosis (5.1%)
- Tachycardia (4.8%)
- Initial insomnia (4.3%)
- Depressed mood (3.9%)
- Palpitations (3.1%)
- Nervousness (3.1%)
- Restlessness (3.1%)
- Tremor (2.7%)
- Upper respiratory tract infection (2.2%)
- Agitation (2.2%)
- Muscle tightness (1.9%)
- Vertigo (1.7%)
- Vision blurred (1.7%)
- Anorexia (1.7%)
- Aggression (1.7%)
- Bruxism (1.7%)
- Depression (1.7%)
- Libido decreased (1.7%)
- Oropharyngeal pain (1.7%)
- Affect liability (1.4%)
- Paresthesia (1.2%)
- Sedation (1.2%)
- Tension headache (1.2%)
- Confusional state (1.2%)
- Tension (1.2%)
Jornay PM
- Headache (10%)
- Vomiting (9%)
- Blood pressure diastolic increased (7%)
- Nausea (6%)
- Psychomotor hyperactivity (5%)
- Nasopharyngitis (3%)
- Pharyngitis streptococcal (3%)
- Contusion (3%)
- Back pain (3%)
- Rash (2%)
Metadate CD
- Anorexia (9%)
- Abdominal pain (7%)
- Insomnia (5%)
Frequency Not Defined
Headache
Hypertension
Nausea
Nervousness
Toxic psychosis
Seizures
Tachycardia
Angina
Cardiac arrhythmia
Cerebral occlusion
Increased/decreased pulse
Cerebral arteritis
Cerebral hemorrhage
Raynaud's phenomenom
Vasculitis
Anxiety
Anger
Agitation
Irritability
Vertigo
Fatigue
Erythema multiform
Hyperhidrosis
Rash
Urticaria
Exfoliative dermatitis
Dysmenorrhea
Constipation
Xerostomia
Vomiting
Weight loss
Erectile dysfunction
Muscle tightness
Paresthesia
Blurred vision
Necrotizing vasculitis
Increased cough
Dyspnea
Sinusitis
Upper respiratory tract infection
Postmarketing Reports
Blood and lymphatic system disorders: Pancytopenia, thrombocytopenia, thrombocytopenic purpura
Cardiac disorders: Angina pectoris, bradycardia, extrasystole, supraventricular tachycardia, ventricular extrasystole, hypertension
Eye disorders: Diplopia, mydriasis, visual impairment
General Disorders: Chest pain, chest discomfort, hyperpyrexia, long-term growth suppression
Hepatobiliary disorders: Hepatocellular injury, acute hepatic failure
Immune system disorders: Hypersensitivity reactions such as angioedema, anaphylactic reactions, auricular swelling, bullous conditions, exfoliative conditions, urticaria, pruritus, rashes, eruptions, and exanthemas
Investigations: Alkaline phosphatase increased, bilirubin increased, hepatic enzyme increased, platelet count decreased, white blood cell count abnormal, severe hepatic injury
Musculoskeletal, connective tissue and bone disorders: Arthralgia, myalgia, muscle twitching, rhabdomyolysis
Nervous system disorders: Convulsion, grand mal convulsion, dyskinesia, serotonin syndrome in combination with serotonergic drugs, lethargy, somnolence
Psychiatric disorders: Disorientation, hallucination, hallucination auditory, hallucination visual, libido changes, mania, depression, drug dependence
Urogenitial system: Priapism
Vascular system: Peripheral vasculopathy, including Raynaud phenomenon
Skin and subcutaneous tissue disorders: Alopecia, erythema
Warnings
Black Box Warnings
Abuse and dependence
This medication has a high potential for abuse and misuse, which can lead to development of substance use disorder, including addiction; misuse and abuse of CNS stimulants can result in overdose and death, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection
Before prescribing this medication, assess each patient’s risk for abuse, misuse, and addiction; educate patients and their families about risks, proper storage of the drug, and proper disposal of any unused drug
Throughout treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction
Contraindications
Hypersensitivity to methylphenidate or other components of product
Coadministration with monoamine oxidase inhibitors (MAOIs) or within 14 days after discontinuing MAOIs
Concerta
- Motor tics or family history or diagnosis of Tourette syndrome
- Glaucoma
- Patients with marked anxiety, tension, and agitation
Metadate CD
- Contains sucrose; do not administer to patients with hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency
Cautions
May cause an increase in blood pressure (BP) and heart rate (HR); monitor for hypertension and tachycardia
Prolonged and painful erections, sometimes requiring surgical intervention, reported with methylphenidate products, including another formulation of methylphenidate hydrochloride extended-release tablets, in both pediatric and adult patients
Priapism was not reported with drug initiation but developed during treatment, often after an increase in dose and during a period of drug withdrawal (drug holidays or during discontinuation); if such reaction occurs, seek immediate medical attention
CNS stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs and symptoms are usually intermittent and generally improve after dose reduction or discontinuing treatment; monitor for digital changes is necessary during treatment; further clinical evaluation (eg, rheumatology referral) may be appropriate for certain patients
Closely monitor growth (weight and height) in pediatric patients treated with stimulants; patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted
Stimulants may lower the convulsive threshold in patients with a history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures; if seizures occur, discontinue drug
Difficulties with accommodation and blurry vision reported
Periodic complete blood cell count, differential, and platelet counts are advised during prolonged therapy
Potential bowel obstruction
- Concerta or Relexxii
- Tablet formulation is nondeformable and does not appreciably change in shape in the GI tract
- Do not administer to patients with pre-existing severe gastrointestinal narrowing conditions, including esophageal motility disorders,small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, cystic fibrosis, history of peritonitis, or chronic intestinal pseudo-obstruction, or Meckel diverticulum
- Use only in patients who can swallow tablets whole
Psychiatric adverse reactions
- CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder
- CNS stimulants may also induce a manic or mixed episode in patients
- Before initiating treatment, screen for risk factors for developing a manic episode (eg, history or family history of suicide, bipolar disorder, and depression)
- CNS stimulants at recommended doses, may cause psychotic or manic symptoms (eg, hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania; consider discontinuing therapy if such symptoms occur
Abuse, misuse, and addiction
- This medication has a high potential for abuse and misuse; use exposes individuals to risks of abuse and misuse, which can lead to development of a substance use disorder, including addiction; this medication can be diverted for non-medical use into illicit channels or distribution
- Risk of overdose and death is increased with higher doses or unapproved methods of administration, such as snorting or injection
- Educate patients and their families about abuse, misuse, and addiction and proper disposal of any unused drug; advise patients to store amphetamine sulfate in a safe place, preferably locked, and instruct patients to not give medication to anyone else; throughout treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction
Motor and verbal tics, and worsening of Tourette’s Syndrome
- CNS stimulants, including amphetamine sulfate, associated with onset or exacerbation of motor and verbal tics; worsening of Tourette’s syndrome also reported
- Before initiating therapy, assess family history and clinically evaluate patients for tics or Tourette’s syndrome; regularly monitor patients for emergence or worsening of tics or Tourette’s syndrome with therapy, and discontinue treatment if clinically appropriate
Acute angle closure glaucoma
- There have been reports of angle closure glaucoma associated with methylphenidate treatment
- Although mechanism not clear, treated patients considered at risk for acute angle closure glaucoma (eg, patients with significant hyperopia) should be evaluated by ophthalmologist
Increased intraocular pressure and glaucoma
- There have been reports of elevation of intraocular pressure (IOP) associated with methylphenidate treatment
- Prescribe therapy to patients with open-angle glaucoma or abnormally increased IOP only if benefit of treatment considered to outweigh risk; closely monitor treated patients with history of abnormally increased IOP or open-angle glaucoma
Serious cardiovascular reactions
- Sudden death, stroke, and myocardial infarction report in adults
- Sudden death reported in pediatric patients with structural cardiac abnormalities and other serious heart problems
- Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems
- Further evaluate for developing exertional chest pain, unexplained syncope, or arrhythmias during treatment
Adhansia XR only
- 45-mg capsules contain FD&C yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons
Drug interaction overview
-
MAOIs
- Contraindicated
- Do administer during or within 14 days of discontinuing MAOI treatment
- Coadministration of MAOIs with CNS stimulants can cause hypertensive crisis, which increases the risk of death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure
-
Antihypertensive drugs
- Monitor BP and adjust dose of antihypertensive drugs accordingly
- Methylphenidate may decrease effectiveness of antihypertensive drugs
-
Halogenated anesthetics
- Avoid using methylphenidate on day of surgery
- Methylphenidate concomitantly used halogenated anesthetics may potentiate the risk of sudden BP and HR increase during surgery
-
Risperidone
- Monitor for signs of extrapyramidal symptoms (EPS)
- Dose changes in either risperidone and/or methylphenidate may increase the risk of EPS
-
Gastric pH modulators (Adhansia XR, Cotempla XR-ODT only)
- Monitor and use alternant based on clinical response
- Gastric pH modulators (eg, proton pump inhibitors, H2-blockers) may change the release, pharmacokinetic profiles, and pharmacodynamics of Adhansia XR
Pregnancy & Lactation
Pregnancy
Published studies and postmarketing reports on use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes
Animal data
- No teratogenic effects were observed with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2x and 9x the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m2 basis, respectively
- However, spina bifida was observed in rabbits at a dose 31x the MRHD given to adolescents
- Decrease in pup body weight was observed in a pre- and postnatal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 3.5x the MRHD given to adolescents
Clinical considerations
- CNS stimulant medications can cause vasoconstriction and thereby decrease placental perfusion
- No fetal and/or neonatal adverse reactions reported with use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers
Pregnancy exposure registry
- Monitors pregnancy outcomes in females exposed to ADHD medications
- Encourage providers to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388
Lactation
Limited published literature, based on breast milk sampling from five mothers, reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7
There are no reports of adverse effects on breastfed infant and no effects on milk production; however, long-term neurodevelopmental effects on infants from CNS stimulant exposure are unknown
Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Unknown; may block reuptake of norepinephrine and dopamine into presynaptic neurons; may stimulate CNS similar to amphetamines; may stimulate cerebral cortex and subcortical structures
Absorption
Bioavailability
- Aptensio XR: 101-102%
- Jornay PM: 73.9%
Peak plasma concentration
- ER tablets: 19.3-19.7 ng/mL(72-mg dose); 3.7 ng/mL (18 mg-dose)
- Aptensio XR: 23.47 ng/mL (capsule); 21.78 ng/mL (sprinkle)
Peak plasma time
- ER tablets: 5.5 hr (72-mg dose); 6.8 hr (18-mg dose)
- Adhansia XR: 1.5 hr (1st median range time); 12 hr (2nd median range time)
- Aptensio XR: 2 hr
- Jornay PM: 14 hr
AUC
- ER tablets: 200.9-206.1 ng⋅hr/mL (72-mg dose); 41.8 ng⋅hr/mL (18-mg dose)
- Aptensio XR: 258.1-262.7 ng⋅hr/mL (capsule): 258-262.9 ng⋅hr/mL (sprinkle)
Distribution
Plasma methylphenidate concentrations in adults and pediatric patients 13-17 years decline biexponentially following oral administration
Vd: 2.65 L/kg (d-methylphenidate); 1.8 L/kg ( l-methylphenidate)
Metabolism
Primarily metabolized by de-esterification to PPAA (little or no pharmacologic activity)
Elimination
Half-life
- ER tablets: 3.5 hr (18-mg dose)
- Aptensio XR: 5.09 hr (capsule); 5.43 hr (sprinkle)
- Jornay PM: 5.9 hr
- Metadate CD: 6.8 hr
- Immediate-release tablets: 2.9 hr
Excretion
- Urine: 90% (80% main urinary metabolite PPAA)
Administration
Oral Administration
Do not substitute for other methylphenidate products on an mg-per-mg basis, because of different methylphenidate base compositions and differing pharmacokinetic profiles
Concerta or Relexxii
- Take orally in the morning with or without food
- Swallow tablet whole with liquid; do not chew, divide, or crush
QuilliChew ER
- Extended-release chewable tablet
- Take once in morning
- May take with or without food
-
Switching from other methylphenidate products
- If switching from other methylphenidate products, discontinue that treatment, and titrate with QuilliChew ER using the titration schedule (see Pediatric Dosing)
Methylin ER tablet
- Swallow whole; do not crush or chew
- Take 30-45 minutes before meals
Ritalin
- Ritalin: Swallow whole, do not crush or chew
- Ritalin LA capsule: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately
- Take all formulations 30-45 minutes before meals
Metadate
- Metadate CD: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately; administer once daily in AM
Quillivant XR
- Oral extended-release suspension
- Shake bottle vigorously for at least 10 seconds before measuring dose
- May take with or without food
Aptensio XR
May take with or without food
Advise patients to establish a routine pattern regarding meals
Capsules may be swallowed whole or opened and the entire contents sprinkled onto applesauce and consume immediately
Cotempla XR-ODT
- Take consistently with or without food
- Use dry hands when opening the blister pack
- Do not remove the tablet from the blister pack until just before dosing
- Remove tablet by peeling back foil on blister pack; do not push the tablet through the foil
- Do not store tablet for future use
- Administer immediately after opening by placing the tablet on patient’s tongue and letting it dissolve; do not chew or crush
- Disintegrate in saliva so that it can be swallowed; no liquid is needed to take the tablet
Jornay PM
- Not to be administered in the morning
- Following determination of optimal administration time, advise patients to maintain a consistent dosing time
- Advise patients to take the dose consistently either with or without food
- May take capsule whole, or may be opened and the entire contents sprinkled onto applesauce; if patient is using the sprinkled administration method, the sprinkled applesauce should be consumed immediately and not stored and should be taken in its entirety without chewing; the dose of a single capsule should not be divided and should be taken at the same time
- Periodically reevaluate long term use and adjust dosage as needed
-
Missed dose
- Take dose as soon possible that same evening; if patient remembers the missed dose the following morning, skip missed dose and wait until next scheduled evening administration
-
Switching from other methylphenidate products
- If switching from other methylphenidate products, discontinue that treatment, and titrate with Jornay PM using the titration schedule described above
Adhansia XR
- Swallow whole or open capsule and sprinkle entire contents onto 1 tablespoon of applesauce or yogurt; consume entire mixture immediately or within 10 min
- Take the entire contents of capsule sprinkled on chosen food in its entirety, without chewing
- Discard mixture if not consumed within 10 min; do not store
- Do not divide capsules nor take <1 capsule/day
-
Missed dose
- Do not administer later in the day
- Do not administer additional medication to make up for missed
-
Switching from other methylphenidate products
- Switching from other methylphenidate products: Discontinue current treatment and titrate with Adhansia XR using titration schedule
Storage
Metadate CD: Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F); protect from light and moisture
Concerta. Relexxii: Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F); protect from humidity
Adhansia XR: Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F); protect from light
Extended-release chewable (QuilliChew ER): Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F)
Extended-release orally disintegrating (Cotempla XR-ODT): Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F); store in reusable travel case
Immediate-release (Ritalin): Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F); protect from light
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Quillivant XR oral - | 5 mg/mL (25 mg/5 mL) suspension | ![]() | |
Quillivant XR oral - | 5 mg/mL (25 mg/5 mL) suspension | ![]() | |
Quillivant XR oral - | 5 mg/mL (25 mg/5 mL) suspension | ![]() | |
Quillivant XR oral - | 5 mg/mL (25 mg/5 mL) suspension | ![]() | |
Aptensio XR oral - | 20 mg capsule | ![]() | |
Aptensio XR oral - | 50 mg capsule | ![]() | |
Aptensio XR oral - | 15 mg capsule | ![]() | |
Aptensio XR oral - | 10 mg capsule | ![]() | |
Aptensio XR oral - | 30 mg capsule | ![]() | |
Aptensio XR oral - | 40 mg capsule | ![]() | |
Aptensio XR oral - | 60 mg capsule | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 5 mg tablet | ![]() | |
methylphenidate HCl oral - | 5 mg tablet | ![]() | |
methylphenidate HCl oral - | 5 mg tablet | ![]() | |
methylphenidate HCl oral - | 54 mg tablet | ![]() | |
methylphenidate HCl oral - | 36 mg tablet | ![]() | |
methylphenidate HCl oral - | 27 mg tablet | ![]() | |
methylphenidate HCl oral - | 18 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg chewable tablet | ![]() | |
methylphenidate HCl oral - | 5 mg chewable tablet | ![]() | |
methylphenidate HCl oral - | 2.5 mg chewable tablet | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 54 mg tablet | ![]() | |
methylphenidate HCl oral - | 27 mg tablet | ![]() | |
methylphenidate HCl oral - | 18 mg tablet | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 5 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 54 mg tablet | ![]() | |
methylphenidate HCl oral - | 36 mg tablet | ![]() | |
methylphenidate HCl oral - | 36 mg tablet | ![]() | |
methylphenidate HCl oral - | 27 mg tablet | ![]() | |
methylphenidate HCl oral - | 18 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 54 mg tablet | ![]() | |
methylphenidate HCl oral - | 30 mg capsule | ![]() | |
methylphenidate HCl oral - | 50 mg capsule | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 50 mg capsule | ![]() | |
methylphenidate HCl oral - | 40 mg capsule | ![]() | |
methylphenidate HCl oral - | 27 mg tablet | ![]() | |
methylphenidate HCl oral - | 54 mg tablet | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 5 mg tablet | ![]() | |
methylphenidate HCl oral - | 50 mg capsule | ![]() | |
methylphenidate HCl oral - | 40 mg capsule | ![]() | |
methylphenidate HCl oral - | 20 mg capsule | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 15 mg capsule | ![]() | |
methylphenidate HCl oral - | 10 mg capsule | ![]() | |
methylphenidate HCl oral - | 5 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 2.5 mg chewable tablet | ![]() | |
methylphenidate HCl oral - | 27 mg tablet | ![]() | |
methylphenidate HCl oral - | 54 mg tablet | ![]() | |
methylphenidate HCl oral - | 36 mg tablet | ![]() | |
methylphenidate HCl oral - | 18 mg tablet | ![]() | |
methylphenidate HCl oral - | 36 mg tablet | ![]() | |
methylphenidate HCl oral - | 27 mg tablet | ![]() | |
methylphenidate HCl oral - | 18 mg tablet | ![]() | |
methylphenidate HCl oral - | 5 mg chewable tablet | ![]() | |
methylphenidate HCl oral - | 5 mg tablet | ![]() | |
methylphenidate HCl oral - | 5 mg tablet | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 5 mg/5 mL solution | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 40 mg capsule | ![]() | |
methylphenidate HCl oral - | 10 mg capsule | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 30 mg capsule | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 20 mg capsule | ![]() | |
methylphenidate HCl oral - | 36 mg tablet | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 54 mg tablet | ![]() | |
methylphenidate HCl oral - | 27 mg tablet | ![]() | |
methylphenidate HCl oral - | 54 mg tablet | ![]() | |
methylphenidate HCl oral - | 36 mg tablet | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 18 mg tablet | ![]() | |
methylphenidate HCl oral - | 20 mg capsule | ![]() | |
methylphenidate HCl oral - | 30 mg capsule | ![]() | |
methylphenidate HCl oral - | 36 mg tablet | ![]() | |
methylphenidate HCl oral - | 40 mg capsule | ![]() | |
methylphenidate HCl oral - | 18 mg tablet | ![]() | |
methylphenidate HCl oral - | 30 mg capsule | ![]() | |
methylphenidate HCl oral - | 40 mg capsule | ![]() | |
methylphenidate HCl oral - | 50 mg capsule | ![]() | |
methylphenidate HCl oral - | 20 mg capsule | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 60 mg capsule | ![]() | |
methylphenidate HCl oral - | 40 mg capsule | ![]() | |
methylphenidate HCl oral - | 30 mg capsule | ![]() | |
methylphenidate HCl oral - | 20 mg capsule | ![]() | |
methylphenidate HCl oral - | 10 mg capsule | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 5 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg capsule | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 18 mg tablet | ![]() | |
methylphenidate HCl oral - | 27 mg tablet | ![]() | |
methylphenidate HCl oral - | 30 mg capsule | ![]() | |
methylphenidate HCl oral - | 20 mg capsule | ![]() | |
methylphenidate HCl oral - | 10 mg capsule | ![]() | |
methylphenidate HCl oral - | 60 mg capsule | ![]() | |
methylphenidate HCl oral - | 36 mg tablet | ![]() | |
methylphenidate HCl oral - | 27 mg tablet | ![]() | |
methylphenidate HCl oral - | 40 mg capsule | ![]() | |
methylphenidate HCl oral - | 60 mg capsule | ![]() | |
methylphenidate HCl oral - | 30 mg capsule | ![]() | |
methylphenidate HCl oral - | 54 mg tablet | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 40 mg capsule | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 5 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 27 mg tablet | ![]() | |
methylphenidate HCl oral - | 18 mg tablet | ![]() | |
methylphenidate HCl oral - | 20 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 10 mg tablet | ![]() | |
methylphenidate HCl oral - | 30 mg capsule | ![]() | |
methylphenidate HCl oral - | 60 mg capsule | ![]() | |
methylphenidate HCl oral - | 50 mg capsule | ![]() | |
methylphenidate HCl oral - | 20 mg capsule | ![]() | |
methylphenidate HCl oral - | 10 mg capsule | ![]() | |
methylphenidate HCl oral - | 20 mg capsule | ![]() | |
methylphenidate HCl oral - | 10 mg capsule | ![]() | |
methylphenidate HCl oral - | 30 mg capsule | ![]() | |
methylphenidate HCl oral - | 20 mg capsule | ![]() | |
Ritalin oral - | 20 mg tablet | ![]() | |
Ritalin oral - | 10 mg tablet | ![]() | |
Ritalin oral - | 5 mg tablet | ![]() | |
Concerta oral - | 54 mg tablet | ![]() | |
Concerta oral - | 36 mg tablet | ![]() | |
Concerta oral - | 18 mg tablet | ![]() | |
Concerta oral - | 27 mg tablet | ![]() | |
Metadate ER oral - | 20 mg tablet | ![]() | |
Jornay PM oral - | 20 mg capsule | ![]() | |
Jornay PM oral - | 60 mg capsule | ![]() | |
Jornay PM oral - | 40 mg capsule | ![]() | |
Jornay PM oral - | 100 mg capsule | ![]() | |
Jornay PM oral - | 80 mg capsule | ![]() | |
QuilliChew ER oral - | 40 mg chewable tablet | ![]() | |
QuilliChew ER oral - | 30 mg chewable tablet | ![]() | |
QuilliChew ER oral - | 20 mg chewable tablet | ![]() | |
Ritalin LA oral - | 40 mg capsule | ![]() | |
Ritalin LA oral - | 30 mg capsule | ![]() | |
Ritalin LA oral - | 20 mg capsule | ![]() | |
Ritalin LA oral - | 10 mg capsule | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.